A Phase 3 interventional study of MK0653, ezetimibe / Duration of Treatment: 28 weeks and Comparator: atorvastatin / Duration of Treatment: 28 weeks in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Hypercholesterolemia by Organon & Co. — none open to participants now, none under way, none of them phase 3. Hypercholesterolemia · Organon & Co..
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 18th largest by enrollment of the 81 interventional ones that give a count, is one of 6 that started in 2002, is one of 58 in phase 3, and was the 4th registered.
1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →None of the 91 studies in Hypercholesterolemia by Organon & Co. is open now. The open studies under Hypercholesterolemia, anywhere →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 655 is above the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 321 across the 81 interventional studies, 1,738 across the 10 observational. Of the 91 that completed or were terminated, 43 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 91 studies in Hypercholesterolemia by Organon & Co., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether an investigational medication will be more effective than an approved medication in reducing cholesterol levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To evaluate the effect on the reduction in low density lipoprotein cholesterol (LDL-C) after the initial 6-week treatment period.
Assess safety/tolerability and evaluate effect on HDL-C & on reduction of LDL-C
Evaluate % of pts who attain their NCEP-ATP III goal for LDL-C @ each dose level
No study locations are listed for this record.
The record gives a start of May 2002, a primary completion of Apr 2003 and a completion of Apr 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.